21
Participants
Start Date
May 31, 2012
Primary Completion Date
December 20, 2019
Study Completion Date
June 30, 2020
V1: HGPO + meal and V2: placebo + meal
"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~ * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
V1: placebo 75mg + meal and V2: HGPO 75mg + meal
"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~ * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
UHToulouse, Toulouse
UHBordeaux, Bordeaux
Ministry of Health, France
OTHER_GOV
University Hospital, Toulouse
OTHER